H-Ras, K-Ras, and N-Ras are the main members of Ras superfamily, which bind small molecules GTP and GDP interchangeably and can hydrolyze GTP to GDP. The Ras superfamily consists of more than 150 proteins and these can be classified under at least five sub-families viz:
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Gln61 of loops. Gln61 is a key residue that stabilizes the transition state of GTP hydrolysis to GDP, in addition to participating in the orientation of the nucleophilic attack that is necessary for this reaction. It has been seen that oncogenic mutations of Gln61 reduce the intrinsic GTP hydrolysis rate, thereby rendering the Ras protein constitutively active. The structural differences in GDP-bound Ras (inactive state) and GTP-bound Ras (active state) lies mainly in highly dynamic regions termed Switch I (residues [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] and Switch II (residues 60-70) as shown in Figure 2 , which are required for the interaction of Ras with both upstream as well as downstream partners.
The binding of GTP brings change in structural conformation of side chain of Switch I, via inward reorientation of side chain of Thr35, which facilitates its interaction with the GTP-γ phosphate as well as the Mg 2+ ion. Similarly, the γ-phosphate induces significant changes in the conformation of Switch II through the interaction it establishes with Gly60. 12 Besides its normal function, such as cellular proliferation and differentiation, survival, and gene expression, gain-of function mutations of H-, N-, K-Ras have been found in different types of human cancers. 12, 13 Besides, aberrant
Ras signaling is also implicated in several developmental disorders, known as the cardio-facio-cutaneous diseases (i.e., neurofibromatosis-type I
[NF-1], Costello syndrome, and Noonan syndrome). 14 The normal biological functioning of RAS proteins as described before require post-translational modification, guided by many important enzymes described earlier. These RAS preprocessing enzymes can serve as attractive drug targets. The activity of RAS is largely determined by the type of cofactors that it binds. When it is bound to GTP, it is active and can recruit downstream target proteins, but when it binds GDP, it is rendered inactive and fails to interact with the downstream effectors.
This association of RAS with GTP or GDP is mediated by two enzymes:
guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). GEFSs catalyze the exchange of GDP for GTP whereas
GAPs increase the rate of GTP hydrolysis to GDP plus phosphate. 15 The activated RAS protein can bind and activate downstream effectors, which ultimately produce appropriate signals, such as cell proliferation, survival, and other physiological functions through the activation of various pathways (see Figure 3) .
One of the first mammalian effector of RAS, which has been well studied and characterized is the protein serine/threonine kinase, is RAF. 16, 17 There are three closely related RAF proteins, CRAF1, BRAF, and ARAF, which are known to be activated by RAS-bound GTP. 18 The 23 The activation of all these transcription factors eventually promotes the cell cycle progression.
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In addition to the RAF/MAPK effector pathway, RAS can also interact with another well-characterized effectors ie., phosphatidyl inositol 3-kinases (PI3Ks).
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The activated PI3Ks phosphorylate phosphatidylinositol 34, 35 Besides, PI3K activation also leads to the activation of RAC, a RHO family protein that not only regulates the actin cytoskeleton but also transcription factors, such as nuclear factor-kappa B( NF-κB). [36] [37] [38] RAC activation also seems to be important in RAS-induced transformation. 39, 40 The third well-known effector of RAS include three exchange factors for RAS-related RAL proteins: RAL guanine nucleotide dissociation stimulator (RALGDS), RGL2/RLF, RALGDS-like gene (RGL/RSB2). [41] [42] [43] With the help of these proteins RAS is able to activate RAL, which in turn activates phospholipase D1, CDC42/RAC-GAP-RAL binding protein1 (RALBP1). 44, 45 These RALGDS pathway together with AKT contribute to the inhibition of FORKHEAD transcription factors. 46 These have been involved in arresting cell cycle progression through activation of cyclin dependent kinase inhibitor, KIPI (also known as p27), and apoptosis through expression of the BIM and FAS ligands. 47, 48 Phospholipase Cε is another effector of Ras. 49 It hydrolysis phosphatidylinositol 4,5-bisphosphosphate to diacylglycerol and inositol-1,4,5-triphosphate, which leads to activation of PKC and calcium mobilization. 50 Through the concerted efforts of RAS and its effectors, it is able to regulate a wide array of functions, such as cellular proliferation, survival, apoptosis, and other important physiological processes.
Abnormal RAS Signaling in Tumors Activating Mutation in RAS
The aberrant RAS signaling in tumors can be contributed by several different mutations, mostly activating mutation in tumor cells: 85 % in K-RAS, 15 % in N-RAS, and <1 % in H-RAS. Table 1 shows the frequency of RAS mutations in various human tumors. It is clear from Table 1 that significantly high rates of Ras mutation (>10 %) was found in tumors, such as colon (adenocarcinoma), leukemias (AML), lymphomas (Hodgkin's lymphoma), lung (large-cell carcinoma and non-small-cell carcinoma) and thyroid (anaplastic and folllicular carcinoma). It is also evident from Table 1 that the oncogenic mutation predominately affects the K-Ras locus, with oncogenic K-Ras mutations being detected ranging from 16 to 36 % in various human tumors screened. The activating mutations mostly affect the GTPase activity of RAS leading to accumulation of RAS-bound GTP. 51, 52 These GTP-bound RAS can hyperactivate other downstream effector proteins previously discussed before leading to constitutive abnormal signaling and anarchy within the tumor cell. The impaired ability of Ras mutants to hydrolyze GTP, either intrinsically or in response to GAPs, is responsible for the oncogenic nature of mutations at residues G12, G13, and Q61 in the active site. 53 
GAP Deletion
Ras remains activated due to loss of GAP-accelerated GTP hydrolysis. One such typical example of GAP mutation is the GAPs, neurofibromin encoded by the NF1 tumor suppressor gene. 54 Patients with neurofibromatosis type I inherit onlyone functional NF1 gene and then predisposed to cancer through complete loss of NF1.
Growth Factor Receptor Activation
Ras signaling has also been known to be activated in tumors in which growth factor receptor tyrosine kinase has been overexpressed. The most common example are epidermal growth factor receptor (EGFR) and receptor tyrosine-protein kinase erbB-2 (ERBB2) which are activated and overexpressed in many types of cancer including breast, ovarian, and stomach carcinomas. 55 
Mutation or Amplification of Ras Effectors
It has been found that BRAF is commonly activated by mutation in human tumors, such as melanomas and colon carcinoma. A study of 923 cancer samples reveal that missense mutations occur commonly in the BRAF gene in approximately 70 % of human malignant melanoma and 15 % of colorectal cancers. 56 The major mutation found in tumors is V559E, a substitution of valine by glutamic acid, which occurs in the kinase activation domain resulting in activation of BRAF. 56 The PI3K pathway is known to be activated due to amplification or mutation of PIK3CA encoding catalytic p110α subunit of PI3K in ovarian and cervical tumors. 57, 58 These mutations commonly occur in two conserved regions of the gene, which encode the kinase and helical PTEN is one of the most frequently mutated genes in human cancers.
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Ras Inhibition Strategies
The involvement of aberrant Ras signaling in different kinds of tumors in humans necessitates the development of therapeutic agents, which can restore a normal function in tumor cell. The developments of therapeutics against it have already started and some have successfully managed to enter into phase I-II clinical trials (see Table 2 ). Targetting the aberrant Ras signaling has largely come from indirect inhibition of Ras effectors, such as AKT, MEK-1/2, PI3K, Raf, etc. This Ras signaling inhibition strategies can be categorized into following four inhibition strategies ( Figure 4) ; each one is discussed briefly below.
Prevention of Ras-GTP Formation
Early studies explored the potency of ATP-competitive kinase inhibitors, which were expected to be used for inhibiting nucleotide binding to Ras.
Although the affinity of kinases for ATP are usually in the micromolar range, 65 picomolar nucleotide affinities of Ras combined with millimolar intracellular nucleotide pools complicate the use of GTP-competitive inhibitors. 66 Consequently, strategies that prevent the initial formation of the Ras-GTP complex were investigated.
Libraries of GTP analogs with alternations at the ribose or nucleotide moiety 66 and of pyrazolo [3,4-b] quinoline ribosides 67 yielded molecules with moderately increased affinity compared with GDP and relatively weak inhibitory potency.
Covalent Locking of the GDP-bound State
Because of the high affinity of Ras to GDP, nucleotide exchange requires assistance by GEF proteins such as Son of Sevenless (SOS) or the closely related RasGRF1 to facilitate GTP loading. Early examples of GEF inhibitors were identified from a compound library whose members were originally designed to compete with GDP for nucleotide binding.
SCH53239 and its derivatives target a hydrophobic pocket close to the nucleotide binding site and inhibit the intrinsic nucleotide exchange. 68, 69 On the basis of these studies, a series of derivatives with improved potency and water solubility was designed that is capable of inhibiting the RasGRF1-catalyzed nucleotide exchange in vitro (half-maximum in hibitory concentration [IC50] = 35−320 μM). 70, 71 The orthosteric Ras-GEF interaction inhibitors described above do not discriminate between mutated and wild-type Ras. In an approach to overcome this limitation for mutated K-RasG12C, the thiol function of cysteine 12 was used to covalently trap inhibitors. A set of GDP-derived inhibitors was developed to directly target the nucleotide binding site. 72 The most active compound, SML-8-73-1, covalently binds K-RasG12C even in the presence of millimolar concentrations of GDP and GTP. SML-10-70-1 shows antiproliferative activity in Ras-dependent cells expressing K-RasG12C (EC50 = 27−47 μM). 73 Ostrem et al. 74 reported covalent inhibitors that are selective for mutant cysteine over the wild type as it relies on trapping of the thiol group in Cys12 in common oncogenic mutant (K-Ras G12C) using disulphide- 
Impairment of Post-translational Modification of Ras
Ras-dependent signaling requires the correct intracellular localization of Ras proteins predominantly at the plasma membrane, mediated by membrane-anchoring lipid residues at the C terminus. Therefore, impairment of Ras localization has been explored to inhibit oncogenic Ras signaling. 84 Ras proteins are equipped with lipid groups through a series of post-translational modifications, which include cysteine S-farnesylation, proteolysis, and carboxymethylation at the C terminus of all Ras isoforms and additional cysteine S-palmitoylation of H-Ras and N-Ras. 
